Platelet-to-neutrophil Ratio after Intravenous Thrombolysis Predicts Unfavorable Outcomes in Acute Ischemic Stroke

Mei-Qi Wang¹,#, Ying-Ying Sun¹,#, Yan Wang¹,#, Xiu-Li Yan¹, Hang Jin¹, Xin Sun¹, Peng Zhang², Hong-Jing Zhu¹, Zhen-Ni Guo²,* and Yi Yang¹,2,*

¹Department of Neurology, Stroke Center, Neuroscience Center, The First Hospital of Jilin University, Chang Chun, Jilin, China; ²Department of Neurology, Clinical Trail and Research Center for Stroke, The First Hospital of Jilin University, Chang Chun, Jilin, China

Abstract: Background and Purpose: Platelet-to-neutrophil ratio (PNR) was suggested to be an independent protective predictor for 90-days outcomes in acute ischemic stroke (AIS) patients in previous studies. This study aims to investigate the association between PNR and outcomes of AIS in intravenous thrombolysis (IVT) group.

Methods: Data on acute ischemic stroke patients who received intravenous thrombolysis from April 2015 to March 2019 were collected. We defined the PNR value at admission as pre-IVT PNR and after IVT within 24 h as defined as post-IVT PNR. Clinical outcome indicators included early neurological deterioration (END), hemorrhagic transformation (HT), delayed neurological deterioration (DND), and poor 3-month outcome (3m-mRS >2).

Results: A total of 581 patients were enrolled in the final analysis. The age was 61(53-69) years, and 423(72.8%) were males. Post-IVT PNR was independently associated with hemorrhagic transformation (OR = 0.974; 95%CI = 0.956-0.992; P=0.006), early neurological deterioration (OR = 0.939; 95%CI = 0.913-0.966; P = 0.01), delayed neurological deterioration (OR = 0.949; 95%CI = 0.912-0.988; P = 0.011), and poor outcome (OR = 0.962; 95%CI = 0.948-0.976; P<0.001). PNR level was identified as high (at the cut-off value or above) or low (below the cut-off value) according to receiver operating curve (ROC) analyses on each endpoint. Comparison of early neurological deterioration, hemorrhagic transformation, delayed neurological deterioration, and poor 3-month outcome (3m-mRS >2) between patients at high and low levels for platelet-to-neutrophil ratio (PNR) showed statistical differences (p<0.001).

Conclusion: Post-IVT PNR was independently associated with early neurological deterioration, hemorrhagic transformation, delayed neurological deterioration, and poor 3-month outcome. Lower PNR can predict a worse outcome.

Keywords: Acute ischemic stroke, intravenous thrombolysis, early neurological deterioration, hemorrhagic transformation, delayed neurological deterioration.

1. INTRODUCTION

Stroke is the second leading cause of death worldwide and also the leading cause of long-term disability [1]. Ischemic stroke is the most common type of stroke [2]. An occurrence of acute ischemic stroke (AIS) always leads to the death of brain tissues and focal neurological deficits. Recombinant tissue plasminogen activator (rtPA) is the only thrombolytic agent approved by the FDA for ischemic stroke therapy. But, owing to the limitation of the narrow therapeutic time window (4.5 h from the onset of symptoms of ischemic stroke) and the potential risk of hemorrhagic transformation (HT), only partial patients can benefit from intravenous thrombolysis (IVT) [3].

According to recent studies, the key role of the inflammatory process has been increasingly recognized in thrombosis. It is well known that platelets adhere to the damaged vessel wall at the site of injury and release types of granules containing enzymes after activation [4-6]. Previous studies demonstrated evidences that leukocytes were recruited by thrombi and invoked thrombo-inflammatory response correlating with the degree of organ injury and clinical outcome [7, 8]. Neutrophils rapidly respond to the ischemic site [9] and release reactive oxygen species (ROS), proteases and cytokines, resulting in a series of brain tissue damage including disruption of the blood-brain barrier (BBB) and cerebral edema [10, 11]. Platelet-to-neutrophil ratio (PNR) is a new
biomarker that combines platelets and neutrophil counts. Compared with single platelet counts and neutrophil counts, PNR reflects the severity of both thrombosis and inflammation, revealing the connection between the two processes. One previous study investigated the potential association of PNR with different histological types of ovarian epithelial carcinomas [12]. In the stroke field, a recent study suggested that the level of PNR on admission is associated with the prognosis of AIS patients [13]. No existing studies have reported whether there is a similar association for the AIS patients treated with IVT.

For the first time, we focused on the clinical value of PNR in predicting the outcome in AIS patients treated with IVT. In consideration of IVT, treatment might change the blood cell counts and ratio, and we involved PNR both before and after IVT into the analysis.

2. MATERIALS AND METHODS

2.1. Study Population

Data from this retrospective study were collected at the First Hospital of Jilin University. Acute ischemic stroke patients who received intravenous thrombolysis treatment from April 2015 to March 2019 were included. A total of 616 patients diagnosed with acute ischemic stroke (AIS) accepted intravenous thrombolysis (IVT) rt-PA treatment within 4.5 h of stroke onset. Patients who lost laboratory data (24) and follow-up data (11) were excluded from this study. Finally, 581 patients were included in the study (Fig. 1).

Fig. (1). The flow chart of the study.
Abbreviations: AIS, acute ischemic stroke; END, early neurologic deterioration; HT, hemorrhagic transformation; DND, delayed neurologic deterioration; IVT, intravenous thrombolysis.
A total of 616 patients diagnosed with acute ischemic stroke (AIS) accepted intravenous thrombolysis (IVT) rt-PA treatment within 4.5 h of stroke onset. Patients who lost laboratory data (24) and follow-up data (11) were excluded from this study. Finally, 581 patients were included in the study.

2.2. Data Collection

Based on the clinical manifestations and signs, an experienced clinician determined whether the patient met the clinical case description of acute stroke, and stroke severity was assessed on admission using the National Institute of Health Stroke Scale (NIHSS) score. All patients underwent emergent computerized tomography (CT) scan before IVT to rule out the possibility of hemorrhagic stroke. We recorded baseline characteristics including demographics (age and sex), vascular risk factors (current smoking, current drinking, atrial fibrillation, coronary artery disease, diabetes, hypertension, and prior stroke), past medical history (antihypertensive therapy, antiplatelet therapy, and hypoglycemic therapy) and baseline parameters (including admission blood glucose, admission systolic and diastolic blood pressure levels, and onset-to-treatment time for IV rt-PA). Venous blood samples were collected both at admission and within 24 h after IVT. The PNR value was calculated according to platelet and neutrophil counts both at admission and after thrombolysis therapy. We defined the PNR value at admission as pre-IVT PNR. Similarly, the PNR value after IVT within 24 h was defined as post-IVT PNR. The procedures of this study were in accord with ethical standards of the responsible institutional or regional committee on human experimentation.

2.3. Outcomes

Four clinical outcome indicators included early neurological deterioration, hemorrhagic transformation, delayed neurological deterioration, and poor 3-month outcome. Hemorrhagic transformation was defined as any visible hemorrhage on brain CT within 24 h after thrombolysis. Early neurological deterioration was defined as ≥4-point increase in scores on the NIHSS or dead within 24 h after intravenous thrombolysis. Delayed neurological deterioration was similarly defined as early neurological deterioration but for the period 24 h to 7 d. 3-months clinical outcome was measured using the modified Rankin Scale (mRS). Poor 3-month outcome was defined as an mRS score of 3-6, and good outcome was defined as an mRS score of 0-2.

2.4. Statistical Analysis

Data were analyzed using the Statistical Program for Social Sciences version 22.0 (SPSS, IBM, West Grove, PA, USA). The difference between the 2 groups was tested using the Mann–Whitney U-test for nonparametrically distributed variables. The differences between categorical variables were determined using the χ² test. Median with IQR and percentage were used to describe the distribution of continuous and categorical variables, respectively. The receiver operating characteristic (ROC) curve was used to evaluate the prognosis effect of PNR. Multivariate logistic regression analysis was used to examine risk factors for each endpoint, classified as 1 when present and 0 when absent. P<0.05 was used to establish statistical significance in all comparisons between groups.

3. RESULTS

3.1. Patients’ Characteristics

Of the 581 patients enrolled in our study, the age was 61(53-69) years, and 423(72.8%) were males. The baseline NIHSS score was 9(5-13). The time from stroke onset to IVT infusion was 180(141-230) min. We accessed outcome events of patients who accepted IVT at different time points: 24 h, 24 h-7 d, and 3 months after thrombolysis. Among 581 eligible patients, 50 (8.6%) presented with early neurological deterioration and 82(14.1%) presented with the hemorrhagic transformation (determined by 24 h-head CT) in the first 24 h after IVT. 25(4.3%) developed delayed neurological deterioration in 24 h-7d after IVT. After 3 months, 190(32.7%) patients had poor outcome (3m-mRS>2). Baseline clinical characteristics and outcomes are summarized in Table 1.

3.2. The Association of PNR Levels with END, HT, DND, and Poor 3-month Outcome

We divided all eligible patients into groups according to the presence or absence of each clinical outcome indicators. The post-IVT PNR value was lower in patients who developed any of the 4 clinical outcome indicators [(29.92 vs. 38.06, p<0.01) in early neurological deterioration, (30.73 vs. 38.64, p<0.01) hemorrhagic transformation, (17.18 vs. 37.76, p<0.01) delayed neurological deterioration, (28.92 vs. 41.67, p<0.01) and poor 3-month outcome]. However, lower Pre-PNR value (32.47 vs. 37.19, p = 0.011) was associated with hemorrhagic transformation, but not with the other endpoints. The comparisons of other main characteristics and laboratory results according to the presence/absence of each endpoint are presented in Tables 2 and 3.

3.3. Logistic Regression Analyses

Logistic regression analyses were used for exploring the association between PNR before/after thrombolysis and at 4 different endpoints. All risk factors were introduced into the multivariate logistic regression analysis. The results of the multivariate logistic regression analyses are detailed in Table 4. The value of post-IVT PNR can predict hemorrhagic transformation (OR = 0.974; 95%CI = 0.956-0.992; P = 0.006), early neurological deterioration (OR = 0.939; 95%CI = 0.913-0.966; P = 0.01), delayed neurological deterioration (OR = 0.949; 95%CI = 0.912-0.988; P = 0.011), and poor 3-month outcome (OR = 0.962; 95%CI = 0.948-0.976; P<0.01). However, baseline PNR value had no association with any of the 4 endpoints.

3.4. Receiver Operating Curve Analyses

Receiver operating curve (ROC) analysis results are detailed in Table 5. According to the results, post-IVT PNR has a higher accuracy for prognosis compared with baseline PNR (all p<0.05). Area under curve (AUC) for early neurological deterioration, hemorrhagic transformation, delayed neurological deterioration, and poor 3-month outcome were 0.647 (95% CI = 0.572-0.723, p<0.01), 0.647 (95% CI = 0.584-0.710, p = 0.01), 0.762 (95% CI = 0.637-0.887, p<0.01), and 0.705 (95% CI = 0.660-0.751, p<0.01), respectively.

According to the ROC curves, we calculated the best cutoff values of post-IVT PNR as 37.9(sensitivity 50.8%, specificity 24%) for early neurological deterioration, 35.6
Table 1. Clinical characteristics of the study population.

| Variables                                      | Total (n = 581) |
|------------------------------------------------|-----------------|
| **Demographic data**                           |                 |
| Age, years, median (IQR)                       | 61 (53-69)      |
| Sex (male), n (%)                              | 423 (72.8)      |
| **Risk factors**                               |                 |
| Current smoking, n (%)                         | 326 (56.1)      |
| Current drinking, n (%)                       | 253 (43.5)      |
| Atrial fibrillation, n (%)                    | 27 (4.6)        |
| Coronary artery disease, n (%)                | 116 (20)        |
| Diabetes, n (%)                                | 189 (32.5)      |
| Hypertension, n (%)                            | 302 (52)        |
| Time from stroke onset to IVT infusion (min), median (IQR) | 180 (141-230) |
| Prior stroke, n (%)                            | 88 (15.1)       |
| **Laboratory tests**                           |                 |
| Systolic blood pressure, mmHg, median (IQR)   | 154 (138-165)   |
| Diastolic blood pressure, mmHg, median (IQR)  | 89 (80-98)      |
| Baseline blood glucose, mmol/L, median (IQR)  | 6.92 (6.13-8.65) |
| Baseline NIHSS score, median (IQR)             | 9 (5-13)        |
| Baseline neutrophil (10^9/L), median (IQR)    | 5.41 (3.98-7.44) |
| Baseline PLT (10^9/L), median (IQR)            | 200 (170-231)   |
| Baseline PNR, median (IQR)                     | 36.71 (26.04-51.29) |
| Post-IVT neutrophil (10^9/L), median (IQR)    | 5.39 (4.23-7.26) |
| **Medications**                                |                 |
| Antihypertensive therapy, n (%)               | 200 (34.4)      |
| Antiplatelet therapy, n (%)                   | 73 (12.6)       |
| Hypoglycemic therapy, n (%)                   | 102 (17.6)      |
| Post-IVT PLT (10^9/L), median (IQR)            | 205 (173-237)   |
| Post-IVT PNR, median (IQR)                     | 37.76 (27.16-49.33) |
| **Outcome events**                             |                 |
| END, n (%)                                     | 50 (8.6)        |
| HT, n (%)                                      | 82 (14.1)       |
| DND, n (%)                                     | 25 (4.3)        |
| Poor 3-month outcome, n (%)                   | 190 (32.7)      |

Abbreviations: NIHSS, National Institute of Health Stroke Scale; PLT, Platelet; PNR, Platelet-To-Neutrophil Ratio; IVT, intravenous Thrombolysis; END, Early Neurologic Deterioration; HT, Hemorrhagic Transformation; DND, Delayed Neurological Deterioration.
Table 2. Clinical characteristics of patients according to the presence/absence of END and HT after IVT treatment.

| Variables                                      | Total (n = 581) | No END (n = 531) | END (n = 50) | P      | No HT (n = 499) | HT (n = 82) | P  |
|------------------------------------------------|----------------|-----------------|-------------|--------|----------------|-------------|----|
| Age, years, median (IQR)                       | 61 (53-69)     | 62 (53-69)      | 59.5 (53.5-67.5) | 0.448  | 62 (54-70)     | 57 (50.75-66) | 0.006 |
| Sex (male), n (%)                              | 423 (72.8)     | 385 (72.5)      | 38 (76)     | 0.595  | 358 (71.7)     | 65 (79.3)   | 0.156 |
| Current smoking, n (%)                         | 326 (56.1)     | 300 (56.5)      | 26 (52)     | 0.54   | 277 (55.5)     | 49 (59.8)   | 0.473 |
| Current drinking, n (%)                        | 253 (43.5)     | 235 (44.3)      | 18 (36)     | 0.26   | 212 (42.5)     | 41 (50)     | 0.203 |
| Atrial fibrillation, n (%)                     | 27 (4.6)       | 27 (5.1)        | 0           | 0.102  | 16 (3.2)       | 11 (13.4)   | <0.01 |
| Coronary artery disease, n (%)                 | 116 (20)       | 107 (20.2)      | 9 (18)      | 0.716  | 103 (20.6)     | 13 (15.9)   | 0.315 |
| Diabetes, n (%)                                | 189 (32.5)     | 167 (31.5)      | 22 (44)     | 0.07   | 153 (30.7)     | 36 (43.9)   | 0.018 |
| Hypertension, n (%)                            | 302 (52)       | 271 (51)        | 31 (62)     | 0.138  | 260 (52.1)     | 42 (51.2)   | 0.882 |
| Time from stroke onset to IVT infusion (min), median (IQR) | 180 (141-230)  | 180 (141-230)   | 177.5 (150-225) | 0.992  | 179 (138-227)  | 203 (153.75-236.25) | 0.109 |
| Prior stroke, n (%)                            | 88 (15.1)      | 81 (15.3)       | 7 (14)      | 0.813  | 75 (15)        | 13 (15.9)   | 0.847 |
| Systolic blood pressure, mmHg, median (IQR)    | 154 (138-165)  | 154 (138-165)   | 156.5 (144.25-167.25) | 0.271  | 154 (138-165)  | 154 (139.5-165) | 0.910 |
| Diastolic blood pressure, mmHg, median (IQR)   | 89 (80-98)     | 89 (80-98)      | 89.5 (80-98) | 0.988  | 89 (80-98)     | 89 (82-98)  | 0.390 |
| Antihypertensive therapy, n (%)                | 200 (34.4)     | 183 (34.5)      | 17 (34)     | 0.947  | 172 (34.5)     | 28 (34.1)   | 0.955 |
| Antiplatelet therapy, n (%)                    | 73 (12.6)      | 62 (11.7)       | 11 (22)     | 0.035  | 56 (11.2)      | 17 (20.7)   | 0.016 |
| Hypoglycemic therapy, n (%)                    | 102 (17.6)     | 89 (16.8)       | 13 (26)     | 0.101  | 83 (16.6)      | 19 (23.2)   | 0.149 |
| Baseline blood glucose, mmol/L, median (IQR)   | 6.92 (6.13-8.65) | 6.92 (6.14-8.65) | 7.03 (5.97-9.06) | 0.815  | 6.92 (6.09-8.62) | 6.91 (6.18-9.56) | 0.444 |
| Baseline NIHSS score, median (IQR)             | 9 (5-13)       | 9 (5-13)        | 6 (3-10)    | <0.01  | 8 (5-12)       | 12 (8-15)   | <0.01 |
| Baseline neutrophil (109/L), median (IQR)      | 5.41 (3.98-7.44) | 5.38 (3.95-7.38) | 5.65 (4.33-7.74) | 0.194  | 5.38 (3.94-7.17) | 6.17 (4.22-8.39) | 0.038 |
| Baseline PLT (109/L), median (IQR)             | 200 (170-231)  | 198 (168-230)   | 213 (191.25-243.25) | 0.025  | 201 (170-231)  | 192.5 (169.5-234) | 0.532 |
| Baseline PNR, median (IQR)                     | 36.71 (26.04-51.29) | 36.7 (26.09-51.46) | 37.37 (24.41-51.33) | 0.949  | 37.19 (26.59-52.61) | 32.47 (23.80-42.32) | 0.011 |
| Post-IVT neutrophil (109/L), median (IQR)      | 5.39 (4.23-7.26) | 5.29 (4.16-7.07) | 7.17 (5.20-9.84) | <0.01  | 5.27 (4.13-7.06) | 6.3 (4.84-8.90) | <0.01 |
| Post-IVT PLT (109/L), median (IQR)             | 205 (173-237)  | 204 (172-237)   | 219.5 (191-249.25) | 0.068  | 205 (173-238)  | 204.5 (174.5-237.25) | 0.86 |
| Post-IVT PNR, median (IQR)                     | 37.76 (27.16-49.33) | 38.06 (27.88-50.11) | 29.92 (22.14-38.13) | 0.001  | 38.64 (28.42-50.93) | 30.73 (23.14-41.57) | <0.01 |

Abbreviations: END, Early Neurologic Deterioration; HT, Hemorrhagic Transformation; NIHSS, National Institute of Health Stroke Scale; PLT, Platelet; PNR, Platelet-to-Neutrophil Ratio; IVT, Intravenous Thrombolysis.
| Variables                              | Total (n = 581) | No DND (n = 556) | DND (n = 25) | P     | Good 3-month outcome (n = 391) | Poor 3-month outcome (n = 190) | P     |
|----------------------------------------|-----------------|------------------|--------------|-------|-------------------------------|--------------------------------|-------|
| Age, years, median (IQR)              | 61 (53-69)      | 61 (53-69)       | 65 (52-72.5) | 0.349 | 60 (52-68)                    | 63 (54-71)                      | 0.007 |
| Sex (male), n (%)                     | 423 (72.8)      | 406 (73)         | 17 (68)      | 0.581 | 283 (72.4)                    | 140 (73.7)                      | 0.74  |
| Current smoking, n (%)                | 326 (56.1)      | 313 (56.3)       | 13 (52)      | 0.672 | 226 (57.8)                    | 100 (52.6)                      | 0.239 |
| Current drinking, n (%)               | 253 (43.5)      | 245 (44.1)       | 8 (32)       | 0.234 | 171 (43.7)                    | 82 (43.2)                       | 0.895 |
| Atrial fibrillation, n (%)            | 27 (4.6)        | 24 (4.3)         | 3 (12)       | 0.074 | 20 (5.1)                      | 7 (3.7)                         | 0.442 |
| Coronary artery disease, n (%)        | 116 (20)        | 110 (19.8)       | 6 (24)       | 0.606 | 75 (19.2)                     | 41 (21.6)                       | 0.498 |
| Diabetes, n (%)                       | 189 (32.5)      | 175 (31.5)       | 14 (56)      | 0.01  | 117 (29.9)                    | 72 (37.9)                       | 0.054 |
| Hypertension, n (%)                   | 302 (52)        | 283 (50.9)       | 19 (76)      | 0.014 | 190 (48.6)                    | 112 (58.9)                      | 0.019 |
| Time from stroke onset to IVT infusion (min), median (IQR) | 180 (141-230)   | 180 (141-228.75) | 175 (146.5-239) | 0.674 | 182 (144-231)                   | 175 (134.75-230)                      | 0.138 |
| Prior stroke, n (%)                   | 88 (15.1)       | 84 (15.1)        | 4 (16)       | 0.093 | 52 (13.3)                      | 36 (18.9)                       | 0.075 |
| Systolic blood pressure, mmHg, median (IQR) | 154 (138-165)   | 154 (138-165)    | 160 (144-167) | 0.589 | 152 (138-164)               | 157 (142-169)                        | 0.099 |
| Diastolic blood pressure, mmHg, median (IQR) | 89 (80-98)      | 89 (80-98)       | 92 (82.5-99.5) | 0.649 | 89 (80-98)                   | 89 (81-98)                       | 0.599 |
| Antihypertensive therapy, n (%)       | 200 (34.4)      | 188 (33.8)       | 12 (48)      | 0.144 | 124 (31.7)                    | 76 (40)                         | 0.049 |
| Antiplatelet therapy, n (%)           | 73 (12.6)       | 68 (12.2)        | 5 (20)       | 0.252 | 45 (11.5)                     | 28 (14.7)                       | 0.271 |
| Hypoglycemic therapy, n (%)           | 102 (17.6)      | 95 (17.1)        | 7 (28)       | 0.161 | 65 (16.6)                     | 37 (19.5)                       | 0.397 |
| Baseline blood glucose, mmol/L, median (IQR) | 6.92 (6.13-8.65) | 6.88 (6.08-8.64) | 7.27 (6.6-9.37) | 0.166 | 6.8 (6.02-8.62)              | 7.12 (6.28-8.72)                           | 0.154 |
| Baseline NIHSS score, median (IQR)    | 9 (5-13)        | 9 (5-12)         | 14 (9-19)    | 0.002 | 8 (4-11)                      | 12 (8-15)                       | <0.01 |
| Baseline neutrophil (109/L), median (IQR) | 5.41 (3.98-7.44) | 5.38 (3.96-7.27) | 8.09 (4.10-10.76) | 0.056 | 5.25 (3.79-7.15)                 | 5.67 (4.27-8.04)                      | 0.016 |
| Baseline PLT (109/L), median (IQR)    | 200 (170-231)   | 200.5 (170-231)  | 195 (168-232.5) | 0.968 | 197 (170-230)                 | 203 (170-236)                     | 0.260 |
| Baseline PNR, median (IQR)            | 36.71 (26.04-51.29) | 36.82 (26.29-51.57) | 30.77 (17.68-51.04) | 0.118 | 37 (26.57-52.49)              | 36.33 (23.96-48.28)                      | 0.169 |
| Post-IVT neutrophil (109/L), median (IQR) | 5.39 (4.23-7.26) | 5.31 (4.20-7.12) | 9.86 (5.60-14.38) | <0.01 | 4.88 (3.87-6.16)                | 6.83 (5.29-9.55)                      | <0.01 |
| Post-IVT PLT (109/L), median (IQR)    | 205 (173-237)   | 205 (173.25-238) | 204 (164.5-228.5) | 0.701 | 204 (172-237)                 | 208.5 (179-238.75)                      | 0.249 |
| Post-IVT PNR, median (IQR)            | 37.76 (27.16-49.33) | 37.81 (28.01-49.51) | 17.18 (13.33-38.58200) | <0.01 | 41.67 (30.97-52.14)             | 28.92 (20.89-40.64)                      | <0.01 |

**Abbreviations:** DND, Delayed Neurological Deterioration; NIHSS, National Institute of Health Stroke Scale; PLT, Platelet; PNR, Platelet-to-Neutrophil Ratio; IVT, Intravenous Thrombolysis.
Table 4. Multivariate logistic regression analysis of the relationship between PNR and four outcome events.

| Dependent Variables                  | Baseline Data | Post-IVT Data |
|--------------------------------------|---------------|---------------|
|                                      | OR            | 95% CI        | P*  | OR            | 95% CI        | P*  |
| END                                  | 0.999         | 0.990-1.008   | 0.775 | 0.939         | 0.913-0.966   | <0.01 |
| HT                                   | 1.000         | 1.000-1.000   | 0.367 | 0.974         | 0.956-0.992   | 0.006 |
| DND                                  | 0.993         | 0.966-1.022   | 0.647 | 0.949         | 0.912-0.988   | 0.011 |
| Poor 3-month outcome                 | 1.000         | 1.000-1.000   | 0.797 | 0.962         | 0.949-0.976   | <0.01 |

*Adjusted for age, sex, current smoking, current drinking, hypertension, diabetes, atrial fibrillation, prior stroke, time from stroke onset to r-tPA infusion, coronary artery disease, systolic blood pressure, diastolic blood pressure, antihypertensive therapy, antplatelet therapy, hypoglycemic therapy, baseline blood glucose, and NIHSS score at baseline.

Fig. (2). Comparison of endpoints between patients at high and low levels for platelet-to-neutrophil ratio (PNR).

Abbreviations: END, early neurologic deterioration; HT, hemorrhagic transformation; DND, delayed neurological deterioration. (A higher resolution / colour version of this figure is available in the electronic copy of the article).

PNR level was identified as high (at the cut-off value or above) or low (below the cut-off value) according to receiver operating curve (ROC) analyses on each endpoint. The results showed that patients of lower post-IVT PNR level tended to have higher percentage of worse outcomes.

4. DISCUSSION

In this study, we found that 24-h post IVT PNR was associated with early neurological deterioration, hemorrhagic transformation, delayed neurological deterioration, and poor 3-month outcome. Lower post-IVT PNR level could predict worse outcomes. Nevertheless, pre-PNR before IVT was not
Acute ischemic stroke may present a state of peripheral blood process of thrombosis and inflammation. Patients of severe occurrence of hemorrhagic transformation or other dangerous conditions may represent a more severe infarction and the occurrence and finally exhaustion [17]. A lower circulating platelet platelet count decrease because of platelet persistent activation and after thrombolysis in 24 h. Our data reflected a dynamic change of PNR value in IVT patients. And based on a large sample size, our results became more reliable and convincing. This study also, for the first time indicated the value of PNR in predicting the prognosis of IVT patients. PNR may become a new predictor in future studies. There are also several common drawbacks of retrospective studies, and a further confounder may exist; Second, all data were collected only in one hospital, and it might lead to selection bias. In addition, intravenous thrombolysis (IVT) treatment can also influence PNR value by changing platelets or neutrophils. Some researchers found that rtPA not only converts plasminogen to plasmin, which degrades fibrin in thrombus and forms soluble fibrin degradation products, but also aggravates platelet activation and aggregation [18, 19]. According to Gensicke et al. [20], decreasing platelet counts are associated with the occurrence of hemorrhagic transformation in IVT-treated stroke patients. Moreover, according to Maestrini et al. [21] higher neutrophil counts after IVT therapy are associated with worse outcomes. And they assessed the potential mechanism for explaining the relationship between poor outcome and neutrophil is the disruption of the blood-brain barrier by releasing MMP-9 and increased reactive oxygen and nitrogen species [21]. All the above studies suggested that post-IVT PNR, rather than the value before thrombolysis treatment, could be a potential predictor for the prognosis of patients.

According to our study, the PNR value after rtPA thrombolysis, but not that before rtPA infusion, was prospectively associated with both short-term outcome and long-term outcome, which suggested the underlying effect of rtPA treatment on platelet and neutrophil.

Compared with other studies, our research has the following strengths: All blood samples were taken both before and after thrombolysis in 24 h. Our data reflected a dynamic change of PNR value in IVT patients. And based on a large sample size, our results became more reliable and convincing. This study also, for the first time indicated the value of PNR in predicting the prognosis of IVT. PNR may become a predictive factor in future studies. There are also several limitations to this study. First, the study had all of the common drawbacks of retrospective studies, and a further confounder may exist; Second, all data were collected only in one hospital, and it might lead to selection bias. In addition, infection and other diseases that may affect inflammation that occurred during treatment were not taken into consideration.

### Table 5. Diagnostic values of the PNR for four outcome events.

| -                | Outcome Events | Threshold | AUC   | 95% CI          | Sensitivity, % | Specificity, % | P      |
|------------------|----------------|-----------|-------|-----------------|----------------|----------------|--------|
| Baseline PNR     | END            | 33.1      | 0.503 | 0.421-0.584     | 72.0%          | 42.7%          | 0.949  |
|                  | HT             | 46.4      | 0.587 | 0.525-0.649     | 34.1%          | 86.6%          | 0.011  |
|                  | DND            | 22.2      | 0.592 | 0.461-0.724     | 86.0%          | 60.0%          | 0.118  |
|                  | Poor 3-month outcome | 49.6 | 0.535 | 0.485-0.585     | 29.9%          | 78.4%          | 0.169  |
| Post-IVT PNR     | END            | 37.9      | 0.647 | 0.572-0.723     | 50.8%          | 24.0%          | 0.010  |
|                  | HT             | 35.6      | 0.647 | 0.584-0.710     | 59.7%          | 30.5%          | <0.001 |
|                  | DND            | 26.8      | 0.762 | 0.637-0.887     | 79.3%          | 72.0%          | <0.001 |
|                  | Poor 3-month outcome | 30.8 | 0.705 | 0.660-0.751     | 76.0%          | 55.8%          | <0.001 |

**Abbreviations**: PNR, Platelet-to-Neutrophil Ratio; IVT, Intravenous Thrombolysis; END, Early Neurologic Deterioration; HT, Hemorrhagic Transformation; DND, Delayed Neurological Deterioration.
CONCLUSION

We found that PNR after thrombolysis therapy was independently associated with early neurological deterioration, hemorrhagic transformation, delayed neurological deterioration, and poor 3-month outcome (mRS>2). In addition, lower PNR could predict a worse outcome. This finding could help neurologists predict and improve stroke outcomes after rtPA treatment in clinical settings. The exact mechanisms need further study.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

This study protocol has been approved by the Ethics Committee of the First Hospital of Jilin University, China.

HUMAN AND ANIMAL RIGHTS

Not applicable.

CONSENT FOR PUBLICATION

Not applicable.

AVAILABILITY OF DATA AND MATERIALS

The authors confirm that the data supporting the findings of this study are available within the article.

FUNDING

This work was supported by the National Natural Science Foundation of China (Grant no. 81771243), the Program for JLUSTRIT (Grant no. 2017TD-12), and the Jilin Provincial Key Laboratory (Grant no. 20190901005JC) to Yi Yang.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

The authors thank the patients and their families and appreciate the study participants for their assistance in this study.

REFERENCES

[1] Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008; 371(9624): 1612-3.
[2] Meschia JF, Brott T. Ischaemic stroke. Eur J Neurol 2018; 25(1): 35-40. http://dx.doi.org/10.1111/ene.13409 PMID: 28800170
[3] Ho WM, Reis C, Akyl O, et al. Pharmacological management options to prevent and reduce ischemic hemorrhagic transformation. Curr Drug Targets 2017; 18(12): 1441-59. http://dx.doi.org/10.2174/1389450113666160181115850 PMID: 27538508
[4] Andrews RK, López JA, Berndt MC. Molecular mechanisms of platelet adhesion and activation. Int J Biochem Cell Biol 1997; 29(1): 91-105. http://dx.doi.org/10.1016/S1357-2255(96)00122-7 PMID: 9076944
[5] Gremmel T, Frelinger AL III, Michelson AD. Platelet physiology. Semin Thromb Hemost 2016; 42(3): 191-204. http://dx.doi.org/10.1055/s-0035-1564835 PMID: 26926581
[6] Holinstat M. Normal platelet function. Cancer Metastasis Rev 2017; 36(2): 195-8. http://dx.doi.org/10.1007/s1055-017-9677-3 PMID: 28667366
[7] Diaco V, Roth SJ, Buocca JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood 1996; 88(1): 146-57. http://dx.doi.org/10.1182/blood.V88.1.146 PMID: 8704169
[8] Hagberg IA, Roald HE, Lyberg T. Adhesion of leukocytes to growing arterial thrombi. Thromb Haemost 1998; 80(5): 852-8. PMID: 9843183
[9] Segel GB, Halterman MW, Lightman MA. The paradox of the neutrophil's role in tissue injury. J Leukoc Biol 2011; 89(3): 359-72. http://dx.doi.org/10.1182/jlb.0910538 PMID: 21097697
[10] Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013; 13(3): 159-75. http://dx.doi.org/10.1038/nri3399 PMID: 23435331
[11] Jickling GC, Liu D, Ander BP, Stamova B, Zhan X, Sharp FR. Targeting neutrophils in ischemic stroke: Translational insights from experimental studies. J Cereb Blood Flow Metab 2015; 35(6): 888-901. http://dx.doi.org/10.1038/jcbfm.2015.45 PMID: 2561432
[12] Bednarska K, Król E, Głowacka E, et al. Analysis of preoperative blood platelet parameters in terms of diversity of epithelial ovarian cancer. Medicine (Baltimore) 2018; 97(12): e180-80. http://dx.doi.org/10.1097/MD.00000000000010180 PMID: 29703010
[13] Jin P, Li X, Chen J, et al. Platelet-to-neutrophil ratio is a prognostic marker for 90-days outcome in acute ischemic stroke. J Clin Neurosci 2019; 63: 110-5. http://dx.doi.org/10.1016/j.jocn.2019.01.028 PMID: 30737090
[14] Ren B, Duan M, Liu Z, et al. Fibrinogen, neutrophil-to-lymphocyte rate and platelet-to-neutrophil rate as novel acute phase indicators in patients with thromboangiitis obliterans. Ann Vasc Surg 2019; 65: 137-144.
[15] Long H, Qin K, Chen J, et al. Biomarkers of gastric cancer-related ischemic stroke and its underlying pathogenesis. Medicine (Baltimore) 2018; 97(17): e0493-93. http://dx.doi.org/10.1097/MD.0000000000010493 PMID: 29703010
[16] Perez-de-Puig I, Miró-Mur F, Ferrer-Ferrer M, et al. Neutrophil recruitment to the brain in mouse and human ischemic stroke. Acta Neuropathol 2015; 129(2): 239-57. http://dx.doi.org/10.1007/s00401-014-1381-0 PMID: 25548073
[17] Chen Y, Xiao Y, Lin Z, et al. The role of circulating platelets microparticles and platelet parameters in acute ischemic stroke patients. J Stroke Cerebrovasc Dis 2015; 24(10): 2313-20. http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2015.06.018 PMID: 26169549
[18] Rubenstein MH, Finn AV, Leinbach RC, et al. Short-term intravenous epifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injury. J Am Coll Cardiol 2004; 43(2): 287-94. http://dx.doi.org/10.1016/j.jacc.2003.08.039 PMID: 14736451
[19] Matosevic B, Knoflach M, Werner P, et al. Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis. Neurology 2013; 80(13): 1216-24. http://dx.doi.org/10.1212/wnl.0b1013e3182897015 PMID: 23486872
[20] Genisicke H, Al Sultan AS, Sribian D, et al. Thrombolysis in Stroke Patients (TRISP) Collaborators. Intravenous thrombolysis and platelet count. Neurology 2018; 90(8): e690-7. http://dx.doi.org/10.1212/wnl.000000000004982 PMID: 29367438
[21] Maestri I, Sribian D, Gauthier S, et al. Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomes. Neurology 2015; 85(16): 1408-16. http://dx.doi.org/10.1212/wnl.000000000002029 PMID: 26362283